Charles (Charlie) McDermott joined Omega Funds in January 2019. Charlie has more than 24 years of experience in the life sciences industry and has held roles of increasing responsibility in drug discovery, regulatory affairs, corporate development, commercial planning, and executive management. Charlie also currently serves as Director at Primmune Therapeutics. Previously, Charlie served as President, Chief Business Officer, and a member of the board of directors of Impact Biomedicines, Inc. Impact was acquired by Celgene in 2018 for $1.1 billion upfront and up to $7 billion overall, if all contingent payments are realized. Prior to joining Impact, Charlie was President and Chief Business Officer of Kala Pharmaceuticals, Inc. Before Joining Kala, Charlie worked at Allergan as Vice President, Global Business Development for the Eye Care and Drug Delivery business units. Before Joining Allergan, Charlie was Associate Director of Business Development at deCODE genetics and before that he worked at Pfizer/Agouron in drug discovery and regulatory affairs. Charlie has a B.A. in biochemistry and molecular biology from UC Santa Cruz, a M.A. in molecular, cellular, and developmental biology from UC Santa Barbara, and a MBA from the University of San Diego.